Sugarmade Signs Binding LOI to Enter Rare Cannabinoid Market via License Agreement for Patented THC-V Rich Chemovars
January 24, 2022
Ryan Allway January 24th, 2022 NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) — via InvestorWire – Sugarmade, Inc. (OTC Pink: SGMD) (“Sugarmade”, “SGMD” or the “Company”) an emerging leader in the licensed cannabis sector, is pleased to announce the signing of a binding Letter of Intent (the “LOI”) with GenCann, Inc.... Read more
InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook
January 5, 2022
Ryan Allway January 5th, 2022 VANCOUVER, British Columbia, Jan. 05, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today issued the following letter from President and CEO Eric A. Adams. Dear Shareholders, Colleagues, and Business... Read more
